Screener
Stoke Therapeutics, Inc. STOK Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income | 18 | 28 |
| Total other income (expense) | 3,415 | 2,917 |
| (Loss) income before income taxes | $(50,003) | $114,157 |
| Provision for income taxes | — | 1,278 |
| Net (loss) income | $(50,003) | $112,879 |
| Net (loss) income per share: | ||
| Basic | $(0.79) | $1.95 |
| Diluted | (0.79) | 1.90 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s income tax?
- Stoke Therapeutics, Inc. (STOK) reported income tax of -$0 in Q1 2026.
- How has Stoke Therapeutics, Inc.'s income tax changed year-over-year?
- Stoke Therapeutics, Inc.'s income tax decreased by 100.0% year-over-year, from $1.28M to -$0.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Stoke Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude